By Carolyn Johnson
Spectacularly high drug prices have become a political punching bag, especially since Turing Pharmaceuticals struck a nerve by increasing the price of a 62-year-old drug by more than 4,000 percent — a mind-boggling increase similar to waking up one day and finding out a gallon of gas costs nearly $100.
Hillary Rodham Clinton announced on Twitter that she’d lay out a plan to help control the “price gouging” in the pharmaceutical industry, which she called “outrageous.” Meanwhile, Sen. Bernie Sanders (I-Vt.) and Rep. Elijah E. Cummings (D-Md.) this summer launched an investigation into exorbitant drug prices and began sending letters to drug companies requesting information about their prices.
The details do indeed turn out to be as insane as they sound. But behind them lurks a real lesson about the way drugs are priced in the United States and what role they actually play in the trillion-dollar fight over controlling health-care costs.
New York-based Turing bought the drug called Daraprim for $55 million this summer. It is used to treat toxoplasmosis, a parasitic infection that can be severe in patients with compromised immune systems, such as HIV, and for pregnant women. Earlier this month, the head of the Infectious Diseases Society of America and the HIV Medicine Association condemned the price increase from $13.50 a pill to $750, noting that the average cost per year for a patient weighing more than 132 pounds would be $634,500
Read more at The Washington Post